GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
Heart Failure Patients Cut Death Risk With Common Diabetes Drug
In a retrospective, multicenter cohort study of 1,518 adults with HFrEF on guideline-directed therapy, GLP-1 receptor agonist use was associ…
Adding a common diabetes medication to standard heart failure treatment may significantly lower death rates.
Qiliqiangxin capsule adjunctive therapy reduces cardiovascular death and hospitalization in patients with heart failure with reduced ejection fraction
A Traditional Chinese Capsule Meets Modern Heart Failure Trials
This systematic review and meta-analysis evaluated Qiliqiangxin capsule as adjunctive therapy in 5,580 patients with heart failure with redu…
Adding a traditional Chinese medicine capsule to standard heart failure care reduced deaths and hospital stays in a review of 24 trials.
Remote monitoring chatbot increased GDMT target dose achievement in recently discharged HFrEF patients compared to standard care
A Simple Chatbot After Heart Failure Hospitalization May Keep You Healthier and Out of the Hospital
This randomized controlled trial enrolled 66 patients with heart failure with reduced ejection fraction (HFrEF) recently discharged from the…
For people with heart failure, consistent digital check-ins after leaving the hospital could be the key to getting the right medication stre…
Research across Heart Failure
Related studies from across the Heart Failure family.
Higher serum total bilirubin levels associated with lower long-term risk in coronary heart disease patients
High bilirubin levels linked to lower heart risk in some cases
This meta-analysis examined the association between serum total bilirubin and major adverse cardiovascular events in patients undergoing per…
New data suggests high bilirubin might protect patients with coronary heart disease from long-term risks, though the evidence is still early…
Bortezomib, cyclophosphamide, and dexamethasone achieved remission in a patient with AL amyloidosis and POEMS syndrome
Treatment shows success for heart failure and rare blood diseases
This case report and literature review describes the treatment of an elderly male with concurrent AL amyloidosis and POEMS syndrome. The pat…
A new look at a complex case reveals how a specific drug combination helped an elderly man with multiple rare conditions.
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios
Incretin Drugs Show Heart Benefits Across Multiple Conditions
This state-of-the-art review synthesizes evidence regarding incretin analogues, specifically GLP-1 receptor agonists and tirzepatide. The re…
GLP-1 drugs and tirzepatide prove heart benefits in diabetes, obesity, heart failure, and more.
Targeting protein acylation modifications via SIRT1 and HDACs may mitigate myocardial injury and inflammation
New ways to treat heart failure through protein modifications
This narrative review explores how protein acylation modifications, including acetylation and lactylation, regulate metabolic signaling in c…
Scientists identify how targeting specific protein changes can help repair heart tissue and reduce inflammation in patients with heart disea…
Percutaneous transcatheter closure using an Amplatzer Muscular VSD Occluder treats left ventricular pseudoaneurysm
Transcatheter Closure Shows Promise for Heart Failure Patients
This case report describes a 75-year-old male with heart failure and a left ventricular pseudoaneurysm successfully treated via percutaneous…
A new procedure using a transcatheter occluder may offer a safe way to treat heart failure caused by a specific heart wall defect.
Remote cardiac rehabilitation supported by mHealth improves exercise capacity in patients with heart failure
Virtual cardiac rehab improves exercise capacity for heart failure patients
Researchers evaluated the impact of structured, remote, and hybrid cardiac rehabilitation programs compared to usual care or center-based mo…
Remote and hybrid heart rehabilitation programs using mobile health tools can improve walking distance and oxygen use in people with heart f…
Neural-immune-cardiovascular axis emerges as therapeutic target in atherosclerosis, hypertension, heart failure
New pathways link nerves and immunity in heart disease
This systematic review synthesizes evidence on the neural-immune-cardiovascular axis in cardiovascular homeostasis and pathogenesis. It exam…
Scientists are mapping how the connection between your nervous system and immune cells may drive conditions like high blood pressure and hea…
Cognitive impairment affects 39% of chronic heart failure patients in pooled analysis
Heart Failure Patients Face High Risk of Cognitive Impairment
This meta-analysis of 14 studies (5,127 patients) reports a pooled cognitive impairment prevalence of 39.3% in chronic heart failure. Risk f…
Nearly 40% of people with chronic heart failure experience cognitive impairment, with specific factors like age and depression increasing th…
Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology
New Framework Links Heart and Kidney Health in Diabetes
This guideline provides a narrative review of the unified cardiometabolic disease (UCD) continuum. It argues that conditions like T2DM, ASCV…
Experts suggest that diabetes, heart failure, and kidney disease may share a single underlying cause rather than being separate conditions.
Persistent insomnia in heart failure is associated with higher anxiety and lower functional capacity
Persistent insomnia linked to higher anxiety in heart failure patients
This secondary analysis of a randomized trial involving 400 patients with heart failure identified distinct insomnia trajectories over 12 mo…
A new look at heart failure data shows that lasting sleep issues are tied to higher anxiety and lower physical ability.
GLP-1 receptor agonists reduce HF worsening events in HFpEF but show no benefit in HFrEF
GLP-1 drugs help heart failure with preserved ejection fraction
This meta-analysis of 11,234 patients with heart failure (HFpEF and HFrEF) found that GLP-1 receptor agonists significantly reduced HF worse…
GLP-1 receptor agonists improve outcomes in heart failure with preserved ejection fraction but not in reduced ejection fraction, according t…
MAGGIC Score Predicts Mortality Outcomes in Patients Undergoing Mitral Valve Transcatheter Edge to Edge Repair
New scoring system helps predict heart failure surgery risks
The MAGGIC score demonstrates significant predictive value for mortality in patients with functional or degenerative mitral regurgitation af…
A new risk score accurately predicts death rates for patients undergoing specific heart valve repairs, outperforming several standard models…
Questions about Heart Failure with Reduced Ejection Fraction
Does adding qiliqiangxin to my current treatment help my heart failure with reduced ejection fraction?
Yes, adding qiliqiangxin to your current treatment may reduce cardiovascular death and heart failure hospitalization in HFrEF, based on a large trial and meta-analysis.
Full answer →Will taking Cimlanod cause low blood pressure in patients with heart failure with reduced ejection fraction?
Yes, Cimlanod significantly increases the risk of low blood pressure (hypotension) in patients with heart failure with reduced ejection fraction, according to a meta-analysis.
Full answer →Does Cimlanod lower the chance of dying from heart failure with reduced ejection fraction?
No, Cimlanod does not significantly lower the chance of dying from heart failure with reduced ejection fraction based on current evidence.
Full answer →